二十二碳六烯酸补充与载脂蛋白E ε4携带者阿尔茨海默病分期的关联:综述
本综述探讨DHA补充与APOE4携带者阿尔茨海默病分期的关联。观察性研究和临床 trials 提示,在痴呆前阶段补充ω-3可能减缓APOE4携带者的早期记忆下降,而在痴呆阶段 trials 结果为阴性。结论认为在痴呆症状出现前对APOE4携带者补充高剂量DHA是有前景的降低AD发病率策略。
要点
- 在痴呆前阶段补充ω-3可能减缓APOE4携带者的早期记忆下降。
- 在AD痴呆阶段的ω-3随机临床试验结果为阴性。
- DHA补充安全性好、可及且经济,值得在APOE4携带者中优化干预。
核心结论
- 在APOE4携带者出现AD痴呆前补充高剂量DHA是有前景的降低AD发病率的方法。
研究设计与样本
- 综述,总结观察性研究、随机临床试验及机制证据,未报告系统检索策略。
主要发现
- 在症状性AD中进行的ω-3随机临床试验结果为阴性。
- 在AD痴呆前阶段的若干观察性研究和临床试验提示ω-3补充可能减缓APOE4携带者的早期记忆下降。
- 认知获益与DHA补充的关联见于痴呆前阶段而非AD痴呆阶段。
关键数值与推荐
- 原文未报告具体数值、比例、阈值、剂量或P值。
临床怎么用
- 对APOE4携带者在AD痴呆症状出现前考虑补充高剂量DHA以降低AD发病风险。
- DHA补充安全性好、可及且经济,支持在APOE4携带者中优化ω-3干预。
- 未来DHA临床试验可借助脑影像进展确定最佳干预时机。
局限性
- 原文未明确报告综述的检索范围与纳入研究数量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The apolipoprotein E ε4 (APOE4) allele identifies a unique population that is at significant risk for developing Alzheimer disease (AD). Docosahexaenoic acid (DHA) is an essential ω-3 fatty acid that is critical to the formation of neuronal synapses and membrane fluidity. Observational studies have associated ω-3 intake, including DHA, with a reduced risk for incident AD. In contrast, randomized clinical trials of ω-3 fatty acids have yielded mixed and inconsistent results. Interactions among DHA, APOE genotype, and stage of AD pathologic changes may explain the mixed results of DHA supplementation reported in the literature. OBSERVATIONS: Although randomized clinical trials of ω-3 in symptomatic AD have had negative findings, several observational and clinical trials of ω-3 in the predementia stage of AD suggest that ω-3 supplementation may slow early memory decline in APOE4 carriers. Several mechanisms by which the APOE4 allele could alter the delivery of DHA to the brain may be amenable to DHA supplementation in predementia stages of AD. Evidence of accelerated DHA catabolism (eg, activation of phospholipases and oxidation pathways) could explain the lack of efficacy of ω-3 supplementation in AD dementia. The association of cognitive benefit with DHA supplementation in predementia but not AD dementia suggests that early ω-3 supplementation may reduce the risk for or delay the onset of AD symptoms in APOE4 carriers. Recent advances in brain imaging may help to identify the optimal timing for future DHA clinical trials. CONCLUSIONS AND RELEVANCE: High-dose DHA supplementation in APOE4 carriers before the onset of AD dementia can be a promising approach to decrease the incidence of AD. Given the safety profile, availability, and affordability of DHA supplements, refining an ω-3 intervention in APOE4 carriers is warranted.
引用
- Yassine HN, Braskie MN, Mack WJ, et al. Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers: A Review. JAMA Neurol. 2017. PMID: 28114437. doi:10.1001/jamaneurol.2016.4899
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。